Lercanil

Lercanidipine Hydrochloride, the active ingredient in Lercanil, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. The drug inhibits L‑type calcium channels in vascular smooth muscle, producing vasodilation and decreasing systemic vascular resistance.

GNH USA supplies Lercanil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable logistics for global distribution through its established network of partners.

Lercanil is a calcium channel blocker indicated for the management of hypertension, acting on the vascular smooth‑muscle tone to lower blood pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping patients achieve target levels and decreasing the risk of cardiovascular complications.

Lercanidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth, usually temporary. - Peripheral edema: swelling of ankles or feet. - Dizziness: may occur upon standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before initiating therapy, consider the following precautions. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be needed. - Elderly patients: start at lower dose and monitor for dizziness. - Concomitant antihypertensives: evaluate risk of additive blood pressure lowering. - CYP3A4 inhibitors: avoid strong inhibitors that may increase drug exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Lercanil can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and increase adverse effects. - Combined use with other potent antihypertensives: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): may reduce effectiveness. - Grapefruit juice: can modestly increase drug exposure. - Diuretics: may enhance blood pressure lowering. - NSAIDs: may attenuate antihypertensive effect.